Blog
RSS FeedPosted by Michael Wonder on 01 Oct 2019
ICER posts draft scoping document for the assessment of treatments for cystic fibrosis
30 September 2019 - Document open to public comment until 21 October 2019. ...
Posted by Michael Wonder on 29 Sep 2019
ICER posts draft scoping document for the assessment of treatments for ulcerative colitis
27 September 2019 - Document open to public comment until 18 October 2019. ...
Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...
Posted by Michael Wonder on 11 Sep 2019
ICER releases draft evidence report on diabetes therapies
11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 10 Sep 2019
ICER's blasted pharma pricing for years, but now drug makers are 'rolling up their sleeves' to cooperate
10 September 2019 - Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 08 Sep 2019
ICER to assess treatments for cystic fibrosis
6 September 2019 - Report will be subject of California Technology Assessment Forum meeting in April 2020; open Input now being ...
Posted by Michael Wonder on 08 Sep 2019
ICER to assess treatments for ulcerative colitis
6 September 2019 - Report will be subject of CTAF meeting in June 2020; open Input now being accepted until 24 ...
Posted by Michael Wonder on 01 Sep 2019
ICER posts draft scoping document for the assessment of treatments for sickle cell disease
30 August 2019 - Document open to public comment until 20 September 2019. ...
Posted by Michael Wonder on 15 Aug 2019
ICER's value framework and patient feedback: Q&A with Steve Pearson
15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...
Posted by Michael Wonder on 10 Aug 2019
ICER to assess treatments for sickle cell disease
9 August 2019 - Report will be subject of New England CEPAC meeting in March 2020; open Input now being ...
Posted by Michael Wonder on 06 Aug 2019
A watchdog group sets aside emotions to assess drugs’ value. Patients say their lives are more than a number.
2 August 2019 - Health economists walk a precarious tightrope: their analyses are quantitative and, presumably, emotion-free. But health care ...
Posted by Michael Wonder on 24 Jul 2019
Patients, backed by ‘dark money’ group, get ready to debate Duchenne drug prices. It will not be boring.
24 July 2019 - Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. ...
Posted by Michael Wonder on 24 Jul 2019
ICER releases draft evidence report on additive cardiovascular disease therapies
24 July 2019 - Public comment period now open until 20 August 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Jul 2019
Aimmune statement on ICER final report on AR101 for peanut allergy
11 July 2019 - Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 ...